Breast Cancer Screening Market Outlook and Strategic Insights by 2027

[Research Report] The breast cancer screening market is expected to reach US$ 6,209.25 Mn by 2027 from US$ 4,638.63 Mn in 2019; it is estimated to grow at a CAGR of 4.8% from 2020 to 2027.

Breast cancer is the most common and widely occurring type of cancer among women; it develops in breast tissues, usually in the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It can also occur in the fatty tissue or fibrous connective tissue within breasts. Early diagnosis of breast cancer is important as it may prevent the condition from becoming critical and ensure a successful curable treatment. The screening methods for the diagnosis of breast cancer include mammography, magnetic resonance imaging (MRI), ultrasound, and others. The foremost goal of screening is to detect disease at its earliest and most treatable stage. The screening procedures identify the early signs of cancer, even before the symptoms begin to show.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Breast Cancer Screening Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Market Insights

Globally Growing Breast Cancer Prevalence

Breast cancer is among the prime causes of deaths in the world, and it is profoundly affecting the quality of life. Thus, it acts as a burden on society if not diagnosed and treated on time. As per the estimations by the American Cancer Society, breast cancer is the most common type of cancer in the US as it caused morbidity in ~234,087 people and lead to 41,904 deaths in 2018. Further, ~276,480 new cases are expected in the country in 2020. As per the Globocan 2019 report, in Germany, the total number of breast cancer cases in 2018 was 71,888, and around the disease lead to ~19,376 deaths in that year. Further, as per the Globocan report, in 2018, there were ~367,900 new cases of breast cancer and 97,972 deaths due to the same in China. In India, NGOs, government agencies, and charity organizations are emphasizing on breast cancer awareness among population to promote early detection, provide comprehensive treatment module, and extend support for breast cancer management. Such initiatives are a result of the increasing prevalence of this type of cancer in the country. As per the Globocan report estimation, in 2018, India reported ~162,468 new breast cancer cases and 87,090 deaths due to the same. Such growing prevalence of breast cancer in different regions around the world is raising the global demand for the screening devices for the same.

Test Type-Based Market Insights

The breast cancer screening market, by product type, is segmented into blood marker tests, imaging test, genetic test, immunohistochemistry test. The imaging test segment held the largest share of the market in 2019, and it is also anticipated to register the highest CAGR in the market during the forecast period.

End-User-Based Insights

On the basis of end user, the breast cancer screening market has been segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitals segment held the largest share of the market in 2019, whereas the diagnostic centers segment is estimated to register the highest CAGR in the market during the forecast period.

Product launches and approvals is a commonly adopted strategy by companies in the breast cancer screening market to expand their footprint worldwide and meet the growing demand by enlarging their product portfolios. They also adopt the strategy of expansion to enlarge customer base across the world, which also permits them to maintain their brand name globally. For instance, in June 2017, Siemens Healthineers received Food and Drug Administration (FDA) approval of product namely syngo.via VB20 which is likely to use for for Molecular Imaging (MI) from Siemens Healthineers — a new release of the company’s established intelligent visualization software for multi-modality imaging.

Breast Cancer Screening Market Regional Insights

The regional trends and factors influencing the Breast Cancer Screening Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Breast Cancer Screening Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Breast Cancer Screening Market Report Scope

Breast Cancer Screening Market Players Density: Understanding Its Impact on Business Dynamics

The Breast Cancer Screening Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Breast Cancer Screening Market are:

1. Koninklijke Philips N.V..
2. HOLOGIC, INC.
3. BD
4. MYRIAD GENETICS, INC.
5. SIEMENS HEALTHCARE GMBH

Disclaimer: The companies listed above are not ranked in any particular order.

Breast Cancer Screening Market – By Product Type

• Blood Marker Test
• Imaging Test
• Genetic Test
• Immunohistochemistry Test

Breast Cancer Screening Market – By Application

• Diagnostic Centers
• Hospitals
• Research Laboratories
• Cancer Institutes

Breast Cancer Screening – By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
• South America
  • Brazil
  • Argentina
  • Rest of South America

Company Profiles

• General Electric Company
• Siemens Healthineers AG
• Exact Sciences Corporation
• Koninklijke Philips N.V.
• Hologic, Inc.
• BD
• Myriad Genetics, Inc.
• Oncocyte Corporation
• Danaher
• POC Medical Systems